Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 16/20 | 0.72 |
| ▸ | KDR | P35968 | 4/20 | 0.71 |
| ▸ | RET | P07949 | 3/20 | 0.71 |
| ▸ | KIF5B | P33176 | 3/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.61 |
| ▸ | FLT1 | P17948 | 1/20 | 0.61 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.61 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL202827 | 0.99 | EGFR (0.73) | EGFRKDRRETKIF5BKCNH2 | |
| SCHEMBL29781309 | 0.99 | EGFR (0.73) | EGFRKDRRETKIF5BKCNH2 | |
| SCHEMBL2456254 | 0.95 | RET (0.72) | EGFRKDRRETKIF5BERBB2 | |
| SCHEMBL10100955 | 0.90 | KDR (0.75) | EGFRKDRRETKIF5BKCNH2 | |
| Hydrochloric Acid SCHEMBL4558015 | 0.89 | EGFR (0.67) | EGFRKDRRETKIF5BERBB2 | |
| SCHEMBL3690394 | 0.87 | EGFR (0.58) | EGFRKDRRETKIF5BKCNH2 | |
| SCHEMBL16016709 | 0.87 | EGFR (0.67) | EGFRKDRRETKIF5BKCNH2 | |
| SCHEMBL13604777 | 0.86 | EGFR (0.69) | EGFRKDRRETKIF5BKCNH2 | |
| SCHEMBL16075710 | 0.86 | EGFR (0.70) | EGFRKDRRETKIF5BFLT1 | |
| SCHEMBL21541701 | 0.86 | EGFR (0.66) | EGFRKDRRETKIF5BKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234263-A1 | Quinazoline Derivatives | ASTRAZENECA (SE) | 2008-09-25 | — | — | US | disclosed |
| EP-1664030-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005026156-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234263-A1 | Quinazoline Derivatives | EGFR, ERBB2, ERBB3 | EGFR 1/4885KDR 137/4885RET 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.